MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025).
Q4 2025 Highlights
- Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion1), in line with upgraded guidance of US$800-$820 million2 (previously US$770-800 million).
- Q4 2025 unaudited Group revenue of approximately US$208 million, up 46% year-over-year.
- Precision Medicine business revenue of approximately US$161 million, up 4% quarter-over-quarter, driven by the successful United States (U.S.) launch of Gozellix® following reimbursement by Centers for Medicare and Medicaid Services (CMS), effective from 1 October 20253.
- First international patients treated in Part 2 (randomized expansion) of the ProstACT® Global Phase 3 study of TLX591-Tx in advanced prostate cancer4.
- First U.S. patients treated in the SOLACE Phase 1 study of TLX090‑Tx in patients with pain from bone metastases5.
- Announced strategic collaboration with Varian, a Siemens Healthineers company, to explore the combination of Telix’s radiopharmaceuticals with external beam radiation therapy (EBRT)6.
Q4 2025 Revenue (Unaudited)
| Revenue (US$M) | Q4 2025 | Q4 2024 | Variation | Q3 2025 | Variation | ||
| Group revenue | 208 | 142 | 46% | 206 | 1% | ||
| Precision Medicine revenue7 | 161 | 139 | 16% | 155 | 4% | ||
| RLS third-party revenue8 | 45 | — | — | 47 | (4)% | ||
Commentary and business highlights
Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Telix’s Precision Medicine business delivered excellent sequential growth in Q4 2025, driven in part by the successful U.S. launch of Gozellix. This revenue growth outpaced a 3% increase in dose volumes, demonstrating the positive impact of our two-product strategy on market share and pricing. With strong early uptake of Gozellix and a robust pipeline of key accounts integrating Gozellix and ARTMS technology, Telix is well positioned for sustained growth in 2026.”
Therapeutics business
- TLX591-Tx (lutetium (177Lu) rosopatamab tetraxetan): Telix is preparing for a readout of safety and dosimetry data from Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate. Part 2 (randomized treatment expansion) has commenced following data safety review and dosed first patients. The study is open for enrollment in Australia, New Zealand and Canada, with further sites to be opened in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan9, …